| Market Cap | ₹10,193Cr |
| ROE | 62.53% |
| P/E Ratio(TTM) | 42.46 |
| EPS(TTM) | 104.25 |
| P/B Ratio | 26.54 |
| Dividend Yield | 0.00% |
| Industry P/E | 40.59 |
| Book Value | 166.75 |
| Debt to Equity | 0.06 |
| Face Value | 10 |
| Managing Director | Himanshu Bakshi |
| Founded | 2024 |
| NSE Symbol | SANOFICONR |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Abbott India | NA (0.00%) | 37.40 | ||
| GlaxoSmithKline Pharmaceuticals | NA (0.00%) | 42.08 | ||
| Pfizer | NA (0.00%) | 26.38 | ||
| Astrazeneca Pharma India | NA (0.00%) | 109.48 |